These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32101847)

  • 1. [Anti-myelin oligodendrocyte glycoprotein antibody-positive neurologic disease, manifested as clinical course of classical Devic's disease: A case report].
    Oji S; Yamaga T; Suzuki M; Tanaka S; Fukaura H; Nomura K
    Rinsho Shinkeigaku; 2020 Mar; 60(3):219-222. PubMed ID: 32101847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Devic's index case: A critical reappraisal - AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?
    Jarius S; Wildemann B
    J Neurol Sci; 2019 Dec; 407():116396. PubMed ID: 31726278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis Optica Spectrum Disorders.
    Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K
    Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J
    Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect Immunofluorescence-Aided Detection of Antimyelin Oligodendrocyte Glycoprotein Antibodies in Neuromyelitis Optica Spectrum Disorder/Myelin Oligodendrocyte Glycoprotein-Associated Antibody Disorder: A Case Series Involving Five Patients.
    Datta D; Mahto M; Sinha U; Kumar S
    Ann Afr Med; 2024 Oct; 23(4):731-736. PubMed ID: 39138928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients.
    Siritho S; Sato DK; Kaneko K; Fujihara K; Prayoonwiwat N
    Mult Scler; 2016 Jun; 22(7):964-8. PubMed ID: 26498263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report.
    Zhang C; Zhang K; Chen B; Yin J; Dong M; Qin Y; Yang X
    BMC Neurol; 2021 Mar; 21(1):109. PubMed ID: 33750325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.
    Zhao Y; Tan S; Chan TCY; Xu Q; Zhao J; Teng D; Fu H; Wei S
    Br J Ophthalmol; 2018 Oct; 102(10):1372-1377. PubMed ID: 29363529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.